Share on LinkedInShare on LinkedIn

ARTICLE · 25 JANUARY 2021

Orange Book Transparency Act Creates Some New Obligations

The Orange Book Transparency Act of 2020, signed into law on January 5, amends section 505(j) of the Federal Food, Drug and Cosmetic Act, codifying and clarifying some patent listing...

United StatesIntellectual Property

The Orange Book Transparency Act of 2020, signed into law on January 5, amends section 505(j) of the Federal Food, Drug and Cosmetic Act, codifying and clarifying some patent listing requirements of existing FDA regulations. It also requires that the FDA provide a list of exclusivities and a report related to certain types of device-related patents.

The act does not significantly impact the form or function of the Orange Book, but several aspects are worth noting.

  • While the FDA is currently considering comments regarding the scope of listable patents, the act provides essentially the same identification of listable patents as the existing related regulations – i.e., "drug substance (active ingredient)," "drug product (formulation or composition)" and "method of using such drug for which approval is sought or has been granted."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from